or Try an Advanced Search...

    Technical Analysis for KYMR - Kymera Therapeutics, Inc.

    Grade Last Price % Change Price Change
    D 38.30 2.41% 0.90
    KYMR closed up 2.41 percent on Monday, May 6, 2024, on 70 percent of normal volume. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Flat Up
    Historical KYMR trend table...
    Date Alert Name Type % Chg
    50 DMA Resistance Bearish 0.00%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
    Stochastic Reached Overbought Strength 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Above Upper BB Strength 0.00%
    Overbought Stochastic Strength 0.00%
    Up 3 Days in a Row Strength 0.00%
    Up 4 Days in a Row Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    Doji - Bearish? Reversal 2.41%
    Older End-of-Day Signals for KYMR ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 16 hours ago
    Up 2% about 19 hours ago
    Rose Above Upper Bollinger Band about 19 hours ago
    60 Minute Opening Range Breakout about 19 hours ago
    Up 1% about 19 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    KYMR Chart by TradingView
    Basic chart:

    Profile

    Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Immunology Solid Tumors Immune System Autoimmune Disease Autoimmunity Rheumatoid Arthritis Hematologic Malignancies Atopic Dermatitis Dermatitis Hidradenitis Suppurativa

    Is KYMR a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 5 Kymera Therapeutics, Inc. (NASDAQ:KYMR) Just Released Its First-Quarter Earnings: Here's What Analysts Think
    May 3 Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2024 Earnings Call Transcript
    May 3 Kymera (KYMR) Q1 Loss Narrower Than Expected, Pipeline in Focus
    May 3 Wall Street Analysts Predict a 34.41% Upside in Kymera Therapeutics (KYMR): Here's What You Should Know
    May 3 Kymera Therapeutics, Inc. (KYMR) Q1 2024 Earnings Call Transcript
    May 3 Kymera Therapeutics Inc (KYMR) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
    May 2 Kymera Therapeutics GAAP EPS of -$0.69 beats by $0.04, revenue of $10.3M misses by $2.75M
    May 2 Kymera Therapeutics Announces First Quarter 2024 Financial Results and Provides a Business Update
    May 1 Kymera Therapeutics Q1 2024 Earnings Preview
    Apr 26 Ovid Therapeutics (OVID) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
    See more KYMR news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 45.31
    52 Week Low 9.6
    Average Volume 606,761
    200-Day Moving Average 26.06
    50-Day Moving Average 38.49
    20-Day Moving Average 35.27
    10-Day Moving Average 35.42
    Average True Range 1.91
    RSI (14) 58.16
    ADX 22.06
    +DI 26.30
    -DI 13.93
    Chandelier Exit (Long, 3 ATRs) 32.79
    Chandelier Exit (Short, 3 ATRs) 38.48
    Upper Bollinger Bands 38.21
    Lower Bollinger Band 32.34
    Percent B (%b) 1.02
    BandWidth 16.64
    MACD Line -0.29
    MACD Signal Line -0.84
    MACD Histogram 0.5499
    Fundamentals Value
    Market Cap 2.27 Billion
    Num Shares 59.4 Million
    EPS -2.86
    Price-to-Earnings (P/E) Ratio -13.39
    Price-to-Sales 46.41
    Price-to-Book 5.59
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 40.30
    Resistance 3 (R3) 40.15 39.33 39.96
    Resistance 2 (R2) 39.33 38.83 39.41 39.85
    Resistance 1 (R1) 38.82 38.51 39.08 38.97 39.74
    Pivot Point 38.00 38.00 38.13 38.08 38.00
    Support 1 (S1) 37.49 37.50 37.75 37.64 36.86
    Support 2 (S2) 36.67 37.18 36.75 36.75
    Support 3 (S3) 36.16 36.67 36.64
    Support 4 (S4) 36.31